How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,153 results for

Mycobacterium Avium Complex

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Linezolid as treatment for pulmonary Mycobacterium avium disease. Full Text available with Trip Pro

Linezolid as treatment for pulmonary Mycobacterium avium disease. To identify the pharmacokinetic/pharmacodynamic parameters and exposures of linezolid in the treatment of pulmonary Mycobacterium avium complex (MAC) disease.Human-derived monocytes infected with MAC were inoculated into hollow-fibre systems for dose-effect and dose-scheduling studies. We mimicked linezolid concentration-time profiles achieved in adult human lungs treated for 28 days. Sampling to confirm that the intended

2017 Journal of Antimicrobial Chemotherapy

82. The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent. Full Text available with Trip Pro

The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent. To determine if ceftaroline and ceftazidime combined with avibactam are efficacious against pulmonary Mycobacterium avium complex (MAC) disease.First, we performed a concentration-effect study of ceftaroline and ceftaroline/avibactam against extracellular MAC in test tubes. Given the difficulty of obtaining avibactam at the time of experimentation, we used a single concentration of commercial ceftazidime/avibactam

2017 Journal of Antimicrobial Chemotherapy

83. A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease. Full Text available with Trip Pro

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease. To compare the efficacy of ceftazidime/avibactam plus tedizolid-based combination regimens with the standard therapy of azithromycin, ethambutol and rifabutin for the treatment of pulmonary Mycobacterium avium complex (MAC) disease.We mimicked the human pulmonary concentration-time profiles of ceftazidime/avibactam and tedizolid in combination, ceftazidime/avibactam

2017 Journal of Antimicrobial Chemotherapy

84. A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting. Full Text available with Trip Pro

A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting. Pulmonary Mycobacterium avium complex (MAC) prevalence is on the rise worldwide. The average therapy duration is 1.5 years, which is associated with poor cure rates. Our objective was to develop a programme to design a combination therapy regimen for pulmonary MAC to be administered for 6 months or less with efficacy in > 90 (...) % of patients.We performed a literature search for the following MeSH headings 'Mycobacterium avium' AND 'pharmacokinetics/pharmacodynamics' in PubMed up to 2016. The findings were then used to identify steps in the programme to design new regimens with faster microbial kill rates than the current standard regimen.First, we designed a strategy for rapid in vitro screening of all antibiotic classes for repurposing against pulmonary MAC. Secondly, we identified and compared maximal microbial kill rates (Emax

2017 Journal of Antimicrobial Chemotherapy

85. Comparative analysis of the genomes of clinical isolates of Mycobacterium avium subsp. hominissuis regarding virulence-related genes. Full Text available with Trip Pro

Comparative analysis of the genomes of clinical isolates of Mycobacterium avium subsp. hominissuis regarding virulence-related genes. Mycobacterium avium subsp. hominissuis is a member of the M. avium complex, a heterogeneous group of bacteria that cause lung infection in immunocompetent patients or disseminated infection in patients with immunosuppression. The bacteria belonging to this complex have variable virulence, depending on the strain considered, and therefore a representative (...) of the most common clinical phenotype was analysed.The genomic sequences of four M. avium subsp. hominissuis isolates obtained from clinical specimens were completed. Mav101, Mav100 and MavA5 were isolated from the blood of patients with AIDS. MavA5 was disseminated from the lung, while Mav3388 was isolated from the lungs of a patient with chronic lung disease. The sequences were annotated using the published Mav104 genome as a blueprint. Functional and virulence analyses of the sequences were carried out

2017 Journal of Medical Microbiology

86. Preliminary Evaluation of a Sitafloxacin-Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium avium Complex Disease Full Text available with Trip Pro

Preliminary Evaluation of a Sitafloxacin-Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium avium Complex Disease Although sitafloxacin (STFX) is known to have a favorable minimum inhibitory concentration for Mycobacterium avium, few studies have evaluated the clinical efficacy of an STFX-containing regimen for pulmonary M avium complex (MAC) disease. To evaluate the clinical efficacy of STFX-containing regimens for relapsed or refractory pulmonary MAC disease, we

2016 Open forum infectious diseases

87. Immune Reconstitution Inflammatory Syndrome Presenting as Mycobacterium Avium Complex Lymphadenitis Full Text available with Trip Pro

Immune Reconstitution Inflammatory Syndrome Presenting as Mycobacterium Avium Complex Lymphadenitis 28000104 2019 03 08 1525-1497 32 6 2017 06 Journal of general internal medicine J Gen Intern Med Immune Reconstitution Inflammatory Syndrome Presenting as Mycobacterium Avium Complex Lymphadenitis. 712-713 10.1007/s11606-016-3956-z Matusz-Fisher Ashley A Department of Internal Medicine, Carolinas HealthCare System, Charlotte, NC, USA. Ashley.Matuszfisher@carolinashealthcare.org. Bodie Wesley W (...) Department of Internal Medicine, Carolinas HealthCare System, Charlotte, NC, USA. Montgomery Thomas T Department of Internal Medicine, Carolinas HealthCare System, Charlotte, NC, USA. eng Journal Article 2016 12 20 United States J Gen Intern Med 8605834 0884-8734 Mycobacterium avium complex human immunodeficiency virus immune reconstitution inflammatory syndrome 2016 09 28 2016 12 05 2016 11 04 2016 12 22 6 0 2016 12 22 6 0 2016 12 22 6 0 ppublish 28000104 10.1007/s11606-016-3956-z 10.1007/s11606-016

2016 Journal of General Internal Medicine

88. Mycobacterium avium-Intracellulare Complex (MAC) Producing a Periportal Pseudotumor in a Patient With HIV and a Normal CD4 Count Full Text available with Trip Pro

Mycobacterium avium-Intracellulare Complex (MAC) Producing a Periportal Pseudotumor in a Patient With HIV and a Normal CD4 Count Mycobacterium avium-intracellulare complex (MAC) is an opportunistic infection typically associated with profound immunosuppression, such as AIDS. The presentation of disseminated MAC can be subtle and mimic systemic symptoms associated with lymphoma; abdominal pseudotumor is an exceptionally rare presentation. In the era of highly active anti-retroviral therapy

2016 ACG case reports journal

89. PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates Full Text available with Trip Pro

PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates The nontuberculous mycobacteria (NTM) cause miscellaneous disorders in humans, especially in the lungs, which present with a variety of radiological features. To date, knowledge of the pathogenic role of the Mycobacterium avium-intracellulare complex (MAC) in the human lung and the definitive criteria for initiating multidrug therapy

2016 Journal of clinical microbiology

90. Broncho-Pleural Fistula with Hydropneumothorax at CT: Diagnostic Implications in Mycobacterium avium Complex Lung Disease with Pleural Involvement Full Text available with Trip Pro

Broncho-Pleural Fistula with Hydropneumothorax at CT: Diagnostic Implications in Mycobacterium avium Complex Lung Disease with Pleural Involvement To determine the patho-mechanism of pleural effusion or hydropneumothorax in Mycobacterium avium complex (MAC) lung disease through the computed tomographic (CT) findings.We retrospectively collected data from 5 patients who had pleural fluid samples that were culture-positive for MAC between January 2001 and December 2013. The clinical findings were (...) investigated and the radiological findings on chest CT were reviewed by 2 radiologists.The 5 patients were all male with a median age of 77 and all had underlying comorbid conditions. Pleural fluid analysis revealed a wide range of white blood cell counts (410-100690/µL). The causative microorganisms were determined as Mycobacterium avium and Mycobacterium intracellulare in 1 and 4 patients, respectively. Radiologically, the peripheral portion of the involved lung demonstrated fibro-bullous changes

2016 Korean Journal of Radiology

91. Relationship Between Lung Cancer and Mycobacterium Avium Complex Isolated Using Bronchoscopy Full Text available with Trip Pro

Relationship Between Lung Cancer and Mycobacterium Avium Complex Isolated Using Bronchoscopy The incidence of Mycobacterium avium complex (MAC)-positive respiratory specimen cultures and MAC lung disease (MACLD) is increasing worldwide. This retrospective study aimed to assess the association between MAC culture-positive bronchoscopy specimens and lung cancer.The medical records of 1382 untreated lung cancer patients between 2003 and 2011 were collected using our hospital database. Of them

2016 The open respiratory medicine journal

92. Pericardial effusion with Mycobacterium avium complex in HIV-infected patients Full Text available with Trip Pro

Pericardial effusion with Mycobacterium avium complex in HIV-infected patients Disseminated atypical Mycobacterium infection is a well-known opportunistic infection in HIV-infected patients with advanced immune deficiency before the introduction of combination antiretroviral therapy. Although the disseminated infection is now rare, few cases of localised infections are reported. A 38-year-old man was diagnosed with HIV infection during asymptomatic sexual health screening. Although he (...) was asymptomatic on diagnosis, he had advanced immunodeficiency; therefore, combination antiretroviral therapy was started immediately. After 5 months of treatment, he developed pericardial effusion. Mycobacterium was detected from a culture of the pericardial fluid and Mycobacterium avium complex was identified using a gene probe test. He was treated with combination therapy for Mycobacterium infection and he fully recovered. Treatment continued for 4 years until he achieved adequate immune recovery. 2016 BMJ

2016 BMJ case reports

93. In Vitro Susceptibility Testing of Bedaquiline Against Mycobacterium avium Complex. Full Text available with Trip Pro

In Vitro Susceptibility Testing of Bedaquiline Against Mycobacterium avium Complex. We performed bedaquiline broth microdilution susceptibility testing using Clinical and Laboratory Standards Institute (CLSI) guidelines on 103 respiratory isolates of Mycobacterium avium complex (MAC), including multidrug-resistant isolates. Approximately 90% of isolates had bedaquiline MICs of ≤0.008 μg/ml, and 102/103 isolates had MICs of ≤0.015 μg/ml. Bedaquiline has excellent potential for use in patients

2016 Antimicrobial Agents and Chemotherapy

94. Thioridazine as Chemotherapy For Mycobacterium avium Complex Diseases. Full Text available with Trip Pro

Thioridazine as Chemotherapy For Mycobacterium avium Complex Diseases. Mycobacterium avium-intracellulare complex (MAC) causes an intractable intracellular infection that presents as chronic pulmonary disease. Currently, therapy consists of ethambutol and macrolides and takes several years to complete. The neuroleptic phenothiazine thioridazine kills mycobacteria by inhibiting the electron transport chain. In several experiments with bacterial populations of up to 10(12) CFU/ml, we failed

2016 Antimicrobial Agents and Chemotherapy

95. Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease

Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Program (...) Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02779049 Recruitment Status : Completed First Posted : May 20, 2016 Last Update Posted : December 15, 2016 Sponsor: National Taiwan University Hospital Information provided

2016 Clinical Trials

96. Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02968212 Recruitment Status : Recruiting First Posted : November 18, 2016 Last Update Posted : February

2016 Clinical Trials

97. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Full Text available with Trip Pro

Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Macrolides, such as azithromycin (AZM) and clarithromycin, are the cornerstones of treatment for Mycobacterium avium complex lung disease (MAC-LD). Current guidelines recommend daily therapy with AZM for cavitary MAC-LD and intermittent therapy for noncavitary MAC-LD, but the effectiveness of these regimens has not been thoroughly investigated. This study evaluated associations between (...) microbiological response and estimated peak plasma concentrations (Cmax) of AZM. The AZM Cmax was measured in patients receiving daily therapy (250 mg of AZM daily, n = 77) or intermittent therapy (500 mg of AZM three times weekly, n = 89) for MAC-LD and daily therapy for Mycobacterium abscessus complex LD (MABC-LD) (250 mg of AZM daily, n = 55). The AZM Cmax was lower with the daily regimen for MAC-LD (median, 0.24 μg/ml) than with the intermittent regimen for MAC-LD (median, 0.65 μg/ml; P < 0.001) or daily

2016 Antimicrobial Agents and Chemotherapy

98. Macrolide-Resistant Mycobacterium avium Complex Lung Infection: An Analysis of 102 Consecutive Cases. (Abstract)

Macrolide-Resistant Mycobacterium avium Complex Lung Infection: An Analysis of 102 Consecutive Cases. The management of macrolide-resistant Mycobacterium avium complex (MR-MAC) pulmonary disease is difficult and is thought to be analogous to that of multidrug-resistant tuberculosis (MDR-TB).This study aimed to clarify the cause of MR-MAC, to see how its management affected outcome, and to compare its prognosis with that of MDR-TB.The medical records of 102 consecutive cases with MR-MAC

2016 Annals of the American Thoracic Society

99. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Full Text available with Trip Pro

Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Macrolide antibiotics are key components of the multidrug treatment regimen for treating lung disease (LD) due to Mycobacterium avium complex (MAC). Despite the emergence of macrolide resistance, limited data are available on macrolide-resistant MAC-LD. This study evaluated the clinical features and treatment outcomes of patients with macrolide

2016 Antimicrobial Agents and Chemotherapy

100. Relapse Versus Reinfection of Mycobacterium avium complex Pulmonary Disease: Patient Characteristics and Macrolide Susceptibility. (Abstract)

Relapse Versus Reinfection of Mycobacterium avium complex Pulmonary Disease: Patient Characteristics and Macrolide Susceptibility. Clinical recurrence of Mycobacterium avium complex (MAC) pulmonary disease occurs in 10 to 40% of patients treated for this disease process. Episodes of clinical recurrence may represent true relapse from the same MAC strain or reinfection with a new strain.The purpose of this study was to investigate the clinical implications of separating patients into these two

2016 Annals of the American Thoracic Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>